Metotab (Methotrexate)

Methotrexate blocks the enzyme dihydrofolate reductase, halting the conversion of folate to its active form. This interruption stops the synthesis of nucleotides needed for DNA, RNA and protein production, leading to reduced proliferation of immune cells and cancer cells, which underlies its anti‑inflammatory and antineoplastic effects.

The dose of Metotab is individualized by the treating physician based on the specific condition, disease severity, patient weight, renal function and other clinical factors. Only a qualified healthcare professional can determine the appropriate dosing regimen.

Methotrexate is classified as pregnancy category X because it is known to cause fetal malformations and embryotoxicity. It is contraindicated in pregnancy and women of childbearing potential must use reliable contraception. Use during breastfeeding is also discouraged, as the drug can be excreted in milk and affect the infant.

To request Metotab, visit the product page on gnhindia.com, enter the desired quantity, and submit the enquiry form. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Compared with biologic DMARDs, methotrexate (Metotab) is an oral, small‑molecule agent that is generally less expensive and has a well‑established efficacy profile for rheumatoid arthritis and psoriasis. However, biologics may be preferred in patients who do not respond adequately to methotrexate or who have contraindications to its use.

Metotab tablets should be stored at temperatures below 25 °C, in their original packaging, and protected from moisture and direct sunlight. Keeping the product in a dry, cool environment helps maintain its stability and potency throughout its shelf life.

Metotab is taken orally, usually with water. Depending on the prescribing regimen, it may be taken once weekly or as directed by the physician. Patients should follow the specific instructions provided by their healthcare professional regarding timing, food intake and any necessary folic acid supplementation.

The most serious risks include severe liver toxicity, pulmonary fibrosis, bone marrow suppression leading to life‑threatening infections, and renal failure. Patients should be monitored regularly for liver enzymes, lung function, blood counts and kidney parameters to detect early signs of these complications.

Metotab is contraindicated in pregnant women, individuals with known hypersensitivity to methotrexate, patients with severe liver disease, uncontrolled infections, and those with significant renal impairment without dose adjustment. It should also be avoided in patients receiving live vaccines due to the risk of uncontrolled infection.